Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2878-2886

  Croner, Roland S ^a   Stürzl, Michael ^a   Rau, Tilman T ^a   Metodieva, Gergana ^b   Geppert, Carol I ^a   Naschberger, Elisabeth ^a   Lausen, Berthold ^b   Metodiev, Metodi V ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Biomarkers; Colorectal cancer; Drug targets; Mass spectrometry; Metastasis; MX1

Indexed keywords

CARRIER PROTEIN; IRF2BP1 PROTEIN, HUMAN; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; PROTEOME; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

COHORT ANALYSIS; COLORECTAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LYMPH NODE METASTASIS; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PHENOTYPE; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR INVASION;

CARRIER PROTEINS; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MASS SPECTROMETRY; MYXOVIRUS RESISTANCE PROTEINS; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEOME; PROTEOMICS; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84908325134     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28929     Document Type: Article

References (32)

1. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
2. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
3. Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature 2011;473:337-42.
4. Croner RS, Guenther K, Foertsch T, et al. Tissue preparation for gene expression profiling of colorectal carcinoma: three alternatives to laser microdissection with preamplification. J Lab Clin Med 2004;143:344-51.
5. Alldridge L, Metodieva G, Greenwood C, et al. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J Proteome Res 2008;7:1458-69.
6. Olsen JV, de Godoy LM, Li G, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 2005;4:2010-21.
7. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367-72.
8. Luber CA, Cox J, Lauterbach H, et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 2010;32:279-89.
9. Cox J, Neuhauser N, Michalski A, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011;10: 1794-805.
10. Gray R. Permax. R package version 1.2.1. 2005, cran.r-project.org.
11. Efron B. Empirical Bayes estimates for large-scale prediction problems. J Am Stat Assoc 2009;104: 1015-28.
12. Efron B, Tibshirani R. Empirical Bayes methods and false discovery rates for microarrays. Genet Epidemiol 2002;23:70-86.
13. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21.
14. Li J, Tibshirani R. Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res 2013;22:519-36.
15. Li J, Witten DM, Johnstone IM, et al. Normalization, testing, and false discovery rate estimation for RNA-sequencing data. Biostatistics 2012;13: 523-38.
16. Croner RS, Schellerer V, Demund H, et al. One step nucleic acid amplification (OSNA)- a new method for lymph node staging in colorectal carcinomas. J Transl Med 2010;8:83.
17. Schellerer VS, Mueller-Bergh L, Merkel S, et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011;3: 445-53.
18. Meyer A, Merkel S, Bruckl W, et al. Cdc2 as prognostic marker in stage UICC II colon carcinomas. Eur J Cancer 2009;45:1466-73.
19. Naschberger E, Croner RS, Merkel S, et al. Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 2008;123: 2120-9.
20. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 2003;421:753-6.
21. Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and posttranslational modifications. Methods 2005;35:265-73.
22. Gerber SA, Rush J, Stemman O, et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003;100:6940-5.
23. Greenwood C, Metodieva G, Al-Janabi K, et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics 2012;75:3031-40.
24. Schwanhausser B, Gossen M, Dittmar G, et al. Global analysis of cellular protein translation by pulsed SILAC. Proteomics 2009;9:205-9.
25. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57-63.
26. Mortazavi A, Williams BA, McCue K, et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-8.
27. Olsen JV, Schwartz JC, Griep-Raming J, et al. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol Cell Proteomics 2009;8:2759-69.
28. Liu H, Sadygov RG, Yates JR, III. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
29. Horisberger MA. Interferons, Mx genes, and resistance to influenza virus. Am J Respir Crit Care Med 1995;152:S67-S71.
30. Horisberger MA, Hochkeppel HK. IFN-alpha induced human 78 kD protein: purification and homologies with the mouse Mx protein, production of monoclonal antibodies, and potentiation effect of IFN-gamma. J Interferon Res 1987;7:331-43.
31. Hartog H, Wesseling J, Boezen HM, et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43: 1895-904.
32. Childs KS, Goodbourn S. Identification of novel co-repressor molecules for Interferon Regulatory Factor-2. Nucleic Acids Res 2003;31:3016-26.